Litcius/Paper detail

Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial

Floris H.B.M. Schreuder, Koen M. van Nieuwenhuizen, Jeannette Hofmeijer, Sarah E. Vermeer, Henk Kerkhoff, Elles Zock, Gert-Jan Luijckx, Gert Messchendorp, Julia van Tuijl, Henri P. Bienfait, Suzanne J. Booij, Ido R. van den Wijngaard, Michel Remmers, A.H.C.M.L. Schreuder, Diederik W.J. Dippel, Julie Staals, Paul J.A.M. Brouwers, Marieke J.H. Wermer, Jonathan M. Coutinho, Vincent I.H. Kwa, Isabelle C. Van Gelder, Roger E. G. Schutgens, Berber Zweedijk, Ale Algra, Jan Willem van Dalen, L. Jaap Kappelle, Gabriël J.E. Rinkel, H. Bart van der Worp, Catharina J.M. Klijn

2021The Lancet Neurology102 citationsDOIOpen Access PDF

Topics & Concepts

MedicineApixabanAtrial fibrillationStroke (engine)Modified Rankin ScaleRandomized controlled trialPopulationClinical endpointInternal medicineSurgeryWarfarinRivaroxabanIschemic strokeEngineeringEnvironmental healthIschemiaMechanical engineeringAtrial Fibrillation Management and OutcomesIntracerebral and Subarachnoid Hemorrhage ResearchAcute Ischemic Stroke Management